We are updating our Privacy Policy and Terms and Conditions to help you clearly understand how your personal information is collected, stored and managed. Learn More
Menu Back toSession-11-Track-3-MSL-Learning-Strategies

Medical Affairs and Scientific Communications Forum

Medical Communication, MSL, and Medical Writing.


Session 11 Track 3: MSL Training – All Things Considered

    Session Chair(s)
      Craig J. Klinger, RPh

      Craig J. Klinger, RPh

      • MSL Trainer, Office of Medical Professional Development
      • Lilly USA, LLC, United States
    During this session we will discuss the challenges of centralized versus decentralized training in a global environment and how you manage content across regions. We will address technology and methods of sharing training to meet educational needs of MSLs across the globe. This session will also provide information on the importance of not just concentrating on on-boarding but also the continuation of MSL education with soft skills to be a more effective MSL. The session is being developed to consist of short introductory presentations to concepts and then a panel discussion with your participation.
    Learning Objective : At the conclusion of this session, participants should be able to:
    • Define the needs to appropriately train an adult-based learner to prepare for a MSL role
    • Describe centralized virus decentralized MSL on-boarding and training
    • Identify technology which can facilitate training in a virtual setting
    • Assemble a learning plan to facilitate on-boarding and continue the education of MSLs
    Speaker(s)
      Craig J. Klinger, RPh

      Speaker

      Craig J. Klinger, RPh

      • MSL Trainer, Office of Medical Professional Development
      • Lilly USA, LLC, United States
      Harry  Varav

      Speaker

      Harry Varav

      • Sr. Manager-Medical Information
      • Amgen Ltd., United States
      Randy  Miller, PharmD

      Speaker

      Randy Miller, PharmD

      • National Director, Medical Science Liaisons
      • Alnylam Pharmaceuticals, United States